Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions reflect a strong focus on the results of the FOURIER and FOURIER-OLE trials, with users emphasizing essential statistics like the reduction in cardiovascular mortality by 23% for those who started treatment earlier. Phrases such as 'long-term benefits' and 'persistently low rates of adverse events' illustrate a positive tone, while words like 'legacy effect' point to deeper theoretical considerations regarding treatment timing and efficacy over time.
The majority of posts generally agree with the study's findings regarding the efficacy and safety of long-term evolocumab treatment.
There is significant curiosity about the research, with many users keen to discuss the implications and details of the findings.
Some posts dive deep into specific data and outcomes, though others remain at a more surface level, reflecting varied engagement.
Many users perceive the publication as having considerable influence on future cardiovascular treatment practices.
Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on placebo followed by 5 years on the drug group starting 2 years earlier: 15% lower cardiovascular risk 23% lower cardiovascular death (!!!) https://t.co/kSfIy1wFAO
#OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs was associated w/ persistently low rates and greater reduction in MACE compared w/ delayed treatment initiation among patients w... https://t.co/9g97s4MZSt https://t.co/y5uN53gdKo
https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️ 8 años de beneficios CV con perfil de seguridad igual que placebo
In an open-label extension of FOURIER up to 8.4y, after the trial, all in this study were given evolocumab (regardless of arm). CV event rates remained lower in those w early vs delayed evolocumab. https://t.co/XlNiwEMQff @CircAHA @DrM_ODonoghue @TIMIStudyGroup #ESCCongress https://t.co/NcotKNexpT
An underrated RCT which underlines the crucial concept of “time-exposure to #LLT” to interpret the magnitude of benefits with long term follow-up. No safety signal and further decrease in #MACE with #LDLc at 30 mg/dL https://t.co/Jvjknl7JwH
Featured in #EHJ's top 10 dyslipidemia papers of '22, FOURIER-OLE highlighted the importance of early and sustained ↓ in LDL-C with PCSK9i. CV mortality ↓ w/evolocumab appears→3 yrs & may grow over time. Long-term Rx ↑ 8y appears safe. @DrM_ODonoghue https://t.co/RtI8HbQqH3
Do statins cause diabetes? This video explores how factors like dosage and type influence diabetes risk in statin users, emphasizing the potential benefits for cardiovascular health versus the risk of new-onset…
Prof Dr Ulrich Laufs discusses the indications for statin use in elderly patients for the primary and secondary prevention of atherosclerotic cardiovascular diseases, focusing on the benefits and side effects of…
The safety of very low LDLC, sacubitril-valsartan's promise in heart failure, and the impact of SGLT2 inhibitors are discussed in this podcast. It analyzes recent findings on treatment outcomes, including…
@JoshJwageman @ApoDudz @SABOURETCardio @JohnKastelein @lipo_fan @Clint_OMeley @AdrianSotoMota @DoctorTro The extension trials are easily Google-able. https://t.co/qJCTcZZR24
@NutritionMadeS3 I don't have our numbers here, but in FOURIER-OLE (the study from which our cohort was derived), 43% of discontinuations were due to patient requests; 28% adverse events (related or not to study drug); 3% protocol-specified criteria; and 25% other reasons. https://t.co/FBlERrqJU3 https://t.co/qKkiGHg2Fm
@jksequoia @ColDaveCrockett @PeterAttiaMD @Amgen The trial you just linked shows that it does reduce the risk of cardiovascular morbidity. The reason it didn't lower mortality was because the trial only lasted 2.2 years. Long-term followup showed that it also lowered CVD mortality https://t.co/6uyTXsVVHM
@raphaels7 And require a pretty tacit hand waving of Fourier-OLE https://t.co/K0n4LxhVdE
@BiotechObserver @Sports_bios How would open label increase the difference between the arms? Yes I’d like to see the earlier data. Doesn’t seem unprecedented. https://t.co/ddNhHUDgHC
@TotalCytopath @DanClintonRN @kaulcsmc @f2harrell If you think ACM HR of 0.97 (0.83–1.13), which took < 30 seconds to find on pubmed, is consistent with the insanity being spewed here, you should have your license to practice under scrutiny https://t.co/BdV2uAl4o0
@TotalCytopath @DanClintonRN @kaulcsmc @f2harrell What off target harms?
@rajaishahin @ProfKausikRay We do have the long term outcome data from Fourier which shows blockade of PCSK9 with an antibody is both safe and effective The average LDL achieved was 0.8 mol/l https://t.co/POHgBCm9zL
@DanClintonRN @auric_phallus @mdavidsonmd https://t.co/Skx7NWPqUD - review the extension study, and understand the bigger picture
One of the joys of being in a field long enough is that you learn which research institutes are basically the ancient aliens of science. Its academia this is almost abuse. UBC needs a safety word, perhaps "occupied Amgen land" would work https://t.co/fSVTEroNdc
RT @CristobMorales:
RT @CristobMorales:
RT @CristobMorales:
RT @CristobMorales:
RT @CristobMorales:
RT @CristobMorales:
@DanClintonRN @Lipoprotein @DrewStearns @Drlipid @nationallipid @DanClintonRN where is this picture from? Please explain below. https://t.co/vQccpAxxiz
Video como para cortar la semana
RT @SABOURETCardio: An underrated RCT which underlines the crucial concept of “time-exposure to #LLT” to interpret the magnitude of benefit…
RT @SABOURETCardio: An underrated RCT which underlines the crucial concept of “time-exposure to #LLT” to interpret the magnitude of benefit…
RT @SABOURETCardio: An underrated RCT which underlines the crucial concept of “time-exposure to #LLT” to interpret the magnitude of benefit…
An underrated RCT which underlines the crucial concept of “time-exposure to #LLT” to interpret the magnitude of benefits with long term follow-up. No safety signal and further decrease in #MACE with #LDLc at 30 mg/dL https://t.co/Jvjknl7JwH
RT @TIMIStudyGroup: Featured in #EHJ's top 10 dyslipidemia papers of '22, FOURIER-OLE highlighted the importance of early and sustained ↓ i…
@anish_koka @drjohnm @sensible_med The other half of links to paint a more complete & IMO accurate picture: Fierce @TIMIStudyGroup response: https://t.co/HtQGlLmI9F #FOURIEROLE 23% ⬇ in CVd: https://t.co/XcvIDYH6EB #ODYSSEYOUTCOMES nominally significant ⬇ all-cause death w similar drug https://t.co/no7w36ruE5
RT @TIMIStudyGroup: Featured in #EHJ's top 10 dyslipidemia papers of '22, FOURIER-OLE highlighted the importance of early and sustained ↓ i…
Featured in #EHJ's top 10 dyslipidemia papers of '22, FOURIER-OLE highlighted the importance of early and sustained ↓ in LDL-C with PCSK9i. CV mortality ↓ w/evolocumab appears→3 yrs & may grow over time. Long-term Rx ↑ 8y appears safe. @DrM_ODonoghue https://t.co/RtI8HbQqH3
@LowCarbEyeDoc See 10.1161/CIRCULATIONAHA.122.061620 flat/slight redxn
RT @ArmandoOterino: O'Donoghue ML,et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulat…
O'Donoghue ML,et al. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. Circulation. 2022 Oct 11;146(15):1109-1119. doi: 10.1161/CIRCULATIONAHA.122.061620.
RT @NutritionMadeS3: Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on place…
Long-term use of Evolocumab demonstrated lowering of LDL and persistently low rates of adverse events for >8 years. AI-generated paper summary here --> https://t.co/ejPykiLUzS https://t.co/bpGLTmZ7Qv
RT @RevistaMFSamfyc: Evolocumab a largo plazo en pacientes con enfermedad cardiovascular aterosclerótica establecida https://t.co/G5HCpNsae…
Evolocumab a largo plazo en pacientes con enfermedad cardiovascular aterosclerótica establecida https://t.co/G5HCpNsaec PMID 36031810
RT @fikkumamoto: Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease https://t.co/uq4DzJJIVZ
RT @fikkumamoto: Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease https://t.co/uq4DzJJIVZ
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease https://t.co/uq4DzJJIVZ
Long term Evolocumab treatment seems to be safe and beneficial. https://t.co/4CBDo7XEvR
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease | Circulation✅✅✅ https://t.co/QSLGajbwvg
This contrasts with LDL-C lowering therapies, in which the effect persists even after both groups receive the same treatment. https://t.co/FBlERrHMW3 https://t.co/5ILc4VZIZ2
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. https://t.co/wsPiJNaJPg
RT @mbotana: Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease https://t.co/cVSM2RBRLV ⬇️ cLDL a la…
RT @mbotana: Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease https://t.co/cVSM2RBRLV ⬇️ cLDL a la…
RT @mbotana: Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease https://t.co/cVSM2RBRLV ⬇️ cLDL a la…
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease https://t.co/cVSM2RBRLV ⬇️ cLDL a largo plazo con #evolocumab asocia tasas persistentemente bajas de eventos q no exceden al placebo y conducen a reducciones adicionales en los mismos https://t.co/ZZ4VvTCG38
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease https://t.co/ktKJVtQkbH
ESC congress 2022 recap#5 Long-term safety and efficacy of PCSK9 inhibitor (evolocumab) were published. Early initiation of evolocumab was more effective than delayed initiation in high-risk patients. #ESCCongres #CVD #cholesterol https://t.co/bvEUJ6E8ci
RT @NutritionMadeS3: Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on place…
RT @NutritionMadeS3: Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on place…
RT @NutritionMadeS3: Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on place…
RT @NutritionMadeS3: Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on place…
RT @NutritionMadeS3: Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on place…
RT @NutritionMadeS3: Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on place…
RT @NutritionMadeS3: Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on place…
RT @NutritionMadeS3: Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on place…
RT @NutritionMadeS3: Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on place…
RT @NutritionMadeS3: Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on place…
RT @NutritionMadeS3: Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on place…
Does it matter WHEN we lower our cholesterol? 7 years of cholesterol-lowering (PCSK9i evolocumab) vs 2 years on placebo followed by 5 years on the drug group starting 2 years earlier: 15% lower cardiovascular risk 23% lower cardiovascular death (!!!) https://t.co/kSfIy1wFAO
Trend new: O'Donoghue ML, ..., Sabatine MS (Circulation) __Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease__ https://t.co/PgHNODdaOe
「CV死亡」のみでも0.77 [0.60-0.99]。全体の到達LDL-C値平均は30mg/dL。 https://t.co/UvdwtV5PCM
RT @kaulcsmc: Is there a true legacy effect in FOURIER-OLE? Unconventional legacy effect definition as Rx not stopped, only LDL contrast el…
Reducción a largo plazo de las LDL con evolocumab se asocia con tasas persistentemente bajas de eventos adversos por más de 8a y condujo a una mayor reducción de los eventos CV #evolocumab #longterm #mortality #risks https://t.co/TinhWeuReJ
RT @cardio_dr_ys: PCSK9iの長期成績:5年フォロー LDL-C中央値 30 mg/dL, 40未満63%。 心血管死23%低下、有害事象は対象群と差なし Long-Term Evolocumab in Patients with Established…
RT @kaulcsmc: Is there a true legacy effect in FOURIER-OLE? Unconventional legacy effect definition as Rx not stopped, only LDL contrast el…
Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease https://t.co/6DWBAZU7zX
RT @CristobMorales: https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️…
RT @kaulcsmc: Is there a true legacy effect in FOURIER-OLE? Unconventional legacy effect definition as Rx not stopped, only LDL contrast el…
RT @cardio_dr_ys: PCSK9iの長期成績:5年フォロー LDL-C中央値 30 mg/dL, 40未満63%。 心血管死23%低下、有害事象は対象群と差なし Long-Term Evolocumab in Patients with Established…
Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease https://t.co/gsU3DZ3QMR
Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease | Circulation✅✅✅ https://t.co/QSLGaiTVDI
RT @CristobMorales: https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️…
PCSK9iの長期成績:5年フォロー LDL-C中央値 30 mg/dL, 40未満63%。 心血管死23%低下、有害事象は対象群と差なし Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease | Circulation https://t.co/mcuwxXmtAD
RT @Teebi_MD:
@ADAlthousePhD https://t.co/NfiDtKYdR4 Adjusting for Confounding Effects of Treatment Switching in FOURIER-OLE Which method to use for robust estimate? Rank preserving structural failure time model(RPSFTM) Inverse probability of censoring weights(IPCW) Two step estimation(TSE)
RT @ArsenaultBenoit: Legacy effect of PCSK9 inhibition. "Long-term LDL-C lowering with evolocumab was associated with persistently low rat…
Is there a true legacy effect in FOURIER-OLE? Unconventional legacy effect definition as Rx not stopped, only LDL contrast eliminated. What is happening at year 4 and 5? Year 2 & 3 outcomes, strictly speaking inconclusive (? lower # of events) https://t.co/NfiDtKYdR4 https://t.co/fH84gPUOc4
RT @Teebi_MD:
RT @Teebi_MD:
RT @pnatarajanmd: In an open-label extension of FOURIER up to 8.4y, after the trial, all in this study were given evolocumab (regardless of…
RT @CircAHA: #OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs w…
RT @CristobMorales: https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️…
RT @pnatarajanmd: In an open-label extension of FOURIER up to 8.4y, after the trial, all in this study were given evolocumab (regardless of…
RT @pnatarajanmd: In an open-label extension of FOURIER up to 8.4y, after the trial, all in this study were given evolocumab (regardless of…
RT @CristobMorales: https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️…
RT @pnatarajanmd: In an open-label extension of FOURIER up to 8.4y, after the trial, all in this study were given evolocumab (regardless of…
RT @CircAHA: #OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs w…
RT @CristobMorales: https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️…
RT @pnatarajanmd: In an open-label extension of FOURIER up to 8.4y, after the trial, all in this study were given evolocumab (regardless of…
RT @pnatarajanmd: In an open-label extension of FOURIER up to 8.4y, after the trial, all in this study were given evolocumab (regardless of…
In an open-label extension of FOURIER up to 8.4y, after the trial, all in this study were given evolocumab (regardless of arm). CV event rates remained lower in those w early vs delayed evolocumab. https://t.co/XlNiwEMQff @CircAHA @DrM_ODonoghue @TIMIStudyGroup #ESCCongress https://t.co/NcotKNexpT
RT @CircAHA: #OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs w…
RT @ArsenaultBenoit: Legacy effect of PCSK9 inhibition. "Long-term LDL-C lowering with evolocumab was associated with persistently low rat…
Released today at #ESCCongress: Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease https://t.co/sMFa3zhPAa #esc2022 #cholesterol #lipids @Amgen
RT @ArsenaultBenoit: Legacy effect of PCSK9 inhibition. "Long-term LDL-C lowering with evolocumab was associated with persistently low rat…
RT @ArsenaultBenoit: Legacy effect of PCSK9 inhibition. "Long-term LDL-C lowering with evolocumab was associated with persistently low rat…
RT @ArsenaultBenoit: Legacy effect of PCSK9 inhibition. "Long-term LDL-C lowering with evolocumab was associated with persistently low rat…
RT @ArsenaultBenoit: Legacy effect of PCSK9 inhibition. "Long-term LDL-C lowering with evolocumab was associated with persistently low rat…
RT @CristobMorales: https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️…
RT @CristobMorales: https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️…
RT @CristobMorales: https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️…
RT @CircAHA: #OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs w…
RT @TIMIStudyGroup: FOURIER Open Label Extension primary results available now @CircAHA @DrM_ODonoghue @rgiugliano @swiviott https://t.co…
RT @CristobMorales: https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️…
RT @CristobMorales: https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️…
RT @CristobMorales: https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️…
RT @CristobMorales: https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️…
RT @CristobMorales: https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️…
https://t.co/P2CcjNDqBG Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease ♥️♥️♥️ 8 años de beneficios CV con perfil de seguridad igual que placebo
RT @TIMIStudyGroup: FOURIER Open Label Extension primary results available now @CircAHA @DrM_ODonoghue @rgiugliano @swiviott https://t.co…
RT @CircAHA: #OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs w…
FOURIER Open Label Extension primary results available now @CircAHA @DrM_ODonoghue @rgiugliano @swiviott https://t.co/RtI8HbPSRv
RT @CircAHA: #OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs w…
RT @CircAHA: #OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs w…
#OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs was associated w/ persistently low rates and greater reduction in MACE compared w/ delayed treatment initiation among patients w... https://t.co/9g97s4MZSt https://t.co/y5uN53gdKo